A 3-month Blinded, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Influenza Vaccination and Tetanus Toxoid Booster Injection in Patients With Relapsing Forms of Multiple Sclerosis (MS)
Phase of Trial: Phase III
Latest Information Update: 16 Jun 2015
At a glance
- Drugs Fingolimod (Primary) ; Influenza virus vaccine; Tetanus vaccine
- Indications Influenza virus infections; Multiple sclerosis; Tetanus
- Focus Pharmacodynamics
- Sponsors Novartis
- 22 Oct 2011 Results presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
- 29 Jun 2011 Additional location [England] identified as reported by ClinicalTrials.gov.
- 22 Sep 2010 New trial record